Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Virology Reports|February 10, 2015
Origin of the dengue virus outbreak in Martin County, Florida, USA 2013Frank D Teets, Moti N Ramgopal, Kristen D Sweeney, et al.AIDS Research and Human Retroviruses|January 26, 2018
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of TreatmentEdwin DeJesus, Bernard Haas, Sorana Segal-Maurer, et al.Antiviral Therapy|October 17, 2014
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized studyBisher Akil, Gary Blick, Debbie P Hagins, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2025
Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled TrialJoseph C Gathe, Edwin Dejesus, Moti N Ramgopal, et al.The Lancet. HIV|May 10, 2019
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialDavid A Wohl, Yazdan Yazdanpanah, Axel Baumgarten, et al.Nature Medicine|October 15, 2025
Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b studyMoti N Ramgopal, Jacob P Lalezari, Ana Gabriela Pires Dos Santos, et al.European Journal of Immunology|May 10, 2024
HIV rebound in HIV controllers is associated with a specific fecal microbiome profileYanhui Cai, Ondrej Podlaha, Steven G Deeks, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2021
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label StudyDebbie Hagins, Princy Kumar, Michael Saag, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2024
Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 TrialOnyema Ogbuagu, Jean-Michel Molina, Ploenchan Chetchotisakd, et al.AIDS (London, England)|October 7, 2025
Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naïve people with HIV: randomized studyDebbie Hagins, Mezgebe Berhe, Gordon E Crofoot, et al.Pageof 2